Back
ESC Premium Access

Use of novel oral anticoagulants in patients with atrial fibrillation and moderate to severe renal dysfunction: findings from a prospective national registry

Session: Poster Session 5 - Atrial fibrillation - Stroke prevention 3
Topic: Oral Anticoagulation
Speaker: Associate Professor A. Barsheshet (Petah Tikva, IL)
Event: ESC Congress 2018

Congress Presentation

Add to my library

Like

About the speaker

Associate Professor Alon Barsheshet

Rabin Medical Center, Petah Tikva (Israel)
1 presentation
0 follower

9 more presentations in this session

Comparison of ischemic stroke risk in atrial fibrillation patients with or without myocardial infarction: A propensity score matched study

Speaker: Doctor G. Yoon (Incheon, KR)

Access
Abstract
Like
Thumbnail

Effectiveness and safety of rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and heart failure

Speaker: Doctor C. Coleman (Storrs, US)

Access
Abstract
Slides
Like
Thumbnail

Prognostic impact of inappropriate doses of direct oral anticoagulants in clinical practice: a subanalysis of the FANTASIIA registry, a prospective, nationwide, real-world, observational study.

Speaker: Doctor M. Ruiz Ortiz (Cordoba, ES)

Access
Abstract
Slides
Like
Thumbnail

Incidence of incomplete surgical left atrial appendage closure

Speaker: Assistant Professor Y. Kim (GangNeung, KR)

Access
Abstract
Slides
Like
Thumbnail

Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes in the daily practice

Speaker: Doctor T. Chao (Taipei, TW)

Access
Abstract
Like
Thumbnail

Access the full session

Poster Session 5 - Atrial fibrillation - Stroke prevention 3

Speakers: Associate Professor A. Barsheshet, Doctor G. Yoon, Doctor C. Coleman, Doctor M. Ruiz Ortiz, Assistant Professor Y. Kim...
Access
Like
Thumbnail

About the event

Image

ESC Congress 2018

25 August - 29 August 2018

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Bristol Myers Squibb Explore sponsored resources
logo Novo Nordisk Explore sponsored resources